News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma reports results from the MANAMI-study in patients with acute myocardial infarction

October 14, 2013

PledPharma AB
Company Announcement

PledPharma reports results from the MANAMI-study in patients with acute
myocardial infarction

Stockholm, 2013-10-14 08:00 CEST (GLOBE NEWSWIRE) -- 

In a small clinical (feasibility) study recently completed at the Regional
Hospital Ryhov in Jönköping, headed by chief physician and assistant professor
Jan-Erik Karlsson, mangafodipir was given as an adjunct to balloon dilatation
(PCI) in patients with acute myocardial infarction. Ten patients received
intravenous (iv) infusion of mangafodipir and 10 patients received saline
(placebo). All patients experienced their first episode of serious infarction
(STEMI). They were transferred to the PCI laboratory for assessment of coronary
artery occlusion and reduction of blood flow to the ischemic region.
Mangafodipir or saline was given iv over 2-5 min just prior to PCI and
reopening of the occluded artery. 

Patients tolerated iv infusion of mangafodipir well without any side-effects.
Magnetic resonance imaging (MRI) at ambulant control showed a tendency of
smaller infarcts (26% vs. 32% for the placebo group) and improved cardiac pump
function (48% vs. 42% for the placebo group) in those who received
mangafodipir. This was in spite of an odd distribution between groups in
disfavor of mangafodipir. Thus the mangafodipir group had a significant longer
period of chest pain (206 min vs. 144 min for the placebo group) prior to PCI.
The complete study results will be presented in forthcoming scientific

"The study shows that a PLED substance like mangafodipir can be given safely to
seriously ill cardiac patients. Another positive finding was the PLED substance
showed a tendency to reduce myocardial infarct size and to improve contractile
function. However, the results needs to be confirmed in further clinical
studies to ascertain that PLED substances protect the heart when used as an
adjunct to PCI in treatment of AMI", says assistant professor Jan-Erik

For further information please contact:

Jacques Näsström, CEO PledPharma, phone +46 73 713 09 79

See also, complementing press release “PledPharma evaluates commercial
potential of myocardial infarction indication” 

About PledPharma
PledPharma is a Swedish specialty pharma company that develops PledOx® for
prevention of severe chemotherapy-induced side effects in cancer patients. Due
to these side effects optimal treatment cannot be carried out. The current
market for supportive cancer care is some SEK 72 billion. PledOx protects
normal cells against oxidative stress. It belongs to a group of compounds named
lowMEM (low Molecular Enzyme Mimetics), and mimics the enzyme Manganese
SuperOxide Dismutase (MnSOD) – the most important endogenous cellular
protectant against devastating oxidative stress. Oxidative stress is a
condition caused by harmful oxygen/nitrogen molecules, e.g., as a result of
chemotherapy treatment. The company is also evaluating opportunities of using
PLED substances in other diseases. PledPharma (STO:PLED) is listed on NASDAQ
OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For
further information, please visit



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10